

# Kelly Chibale

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3030864/publications.pdf>

Version: 2024-02-01

184  
papers

5,060  
citations

76326

40  
h-index

138484

58  
g-index

193  
all docs

193  
docs citations

193  
times ranked

6049  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antimalarial efficacy of MMV390048, an inhibitor of <i>Plasmodium</i> phosphatidylinositol 4-kinase. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	204
2	Design, synthesis and anti-plasmodial evaluation in vitro of new 4-aminoquinoline isatin derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 3249-3261.	3.0	150
3	The State of the Art in Anti-Malarial Drug Discovery and Development. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 1226-1254.	2.1	149
4	The Role of Natural Products in Drug Discovery and Development against Neglected Tropical Diseases. <i>Molecules</i> , 2017, 22, 58.	3.8	139
5	Synthesis and antiplasmodial activity in vitro of new ferrocene-chloroquine analogues. <i>Dalton Transactions</i> , 2003, , 3046-3051.	3.3	130
6	3,5-Diaryl-2-aminopyridines as a Novel Class of Orally Active Antimalarials Demonstrating Single Dose Cure in Mice and Clinical Candidate Potential. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 3479-3487.	6.4	124
7	Antimalarial Pyrido[1,2- <i>a</i> ]benzimidazoles. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 4581-4589.	6.4	94
8	Recent Approaches to Chemical Discovery and Development Against Malaria and the Neglected Tropical Diseases Human African Trypanosomiasis and Schistosomiasis. <i>Chemical Reviews</i> , 2014, 114, 11138-11163.	47.7	91
9	Enone and Chalcone-Chloroquinoline Hybrid Analogues: In Silico Guided Design, Synthesis, Antiplasmodial Activity, in Vitro Metabolism, and Mechanistic Studies. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 3637-3649.	6.4	87
10	Synthesis, Structure and in Vitro Biological Screening of Palladium(II) Complexes of Functionalised Salicylaldimine Thiosemicarbazones as Antimalarial and Anticancer Agents. <i>European Journal of Inorganic Chemistry</i> , 2010, 2010, 3520-3528.	2.0	78
11	Strategies to Combat Multi-Drug Resistance in Tuberculosis. <i>Accounts of Chemical Research</i> , 2021, 54, 2361-2376.	15.6	78
12	Pyrrolo[3,4- <i>c</i> ]pyridine-1,3(2- <i>H</i> )-diones: A Novel Antimycobacterial Class Targeting Mycobacterial Respiration. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 9371-9381.	6.4	74
13	Drug repositioning in the treatment of malaria and TB. <i>Future Medicinal Chemistry</i> , 2011, 3, 1413-1426.	2.3	73
14	Novel Orally Active Antimalarial Thiazoles. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 7713-7719.	6.4	72
15	Anticancer Properties of Distinct Antimalarial Drug Classes. <i>PLoS ONE</i> , 2013, 8, e82962.	2.5	67
16	Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl. <i>Oncogenesis</i> , 2019, 8, 14.	4.9	62
17	Identification of New Human Malaria Parasite <i>Plasmodium falciparum</i> Dihydroorotate Dehydrogenase Inhibitors by Pharmacophore and Structure-Based Virtual Screening. <i>Journal of Chemical Information and Modeling</i> , 2016, 56, 548-562.	5.4	61
18	Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV Pandemic Response Box. <i>Nature Communications</i> , 2021, 12, 269.	12.8	61

#	ARTICLE	IF	CITATIONS
19	Synthesis and in vitro evaluation of gold(I) thiosemicarbazone complexes for antimalarial activity. <i>Journal of Inorganic Biochemistry</i> , 2010, 104, 1079-1083.	3.5	59
20	Quinoline Antimalarials Containing a Dibemethin Group Are Active against Chloroquinone-Resistant <i>Plasmodium falciparum</i> and Inhibit Chloroquine Transport via the <i>P. falciparum</i> Chloroquine-Resistance Transporter (PfCRT). <i>Journal of Medicinal Chemistry</i> , 2011, 54, 6956-6968.	6.4	56
21	Synthesis and biological evaluation of 2-aminothiazole derivatives as antimycobacterial and antiplasmodial agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 560-564.	2.2	56
22	Inhibition of Resistance-Refractory <i>P. falciparum</i> Kinase PKG Delivers Prophylactic, Blood Stage, and Transmission-Blocking Antiplasmodial Activity. <i>Cell Chemical Biology</i> , 2020, 27, 806-816.e8.	5.2	56
23	Synthesis and antimalarial activity in vitro of new ruthenocene-chloroquine analogues. <i>Dalton Transactions RSC</i> , 2002, , 4426-4433.	2.3	54
24	Fast in vitro methods to determine the speed of action and the stage-specificity of anti-malarials in <i>Plasmodium falciparum</i> . <i>Malaria Journal</i> , 2013, 12, 424.	2.3	54
25	Combining Stage Specificity and Metabolomic Profiling to Advance Antimalarial Drug Discovery. <i>Cell Chemical Biology</i> , 2020, 27, 158-171.e3.	5.2	54
26	Thiosemicarbazone Salicylaldiminato-Palladium(II)-Catalyzed Mizoroki-Heck Reactions. <i>Advanced Synthesis and Catalysis</i> , 2010, 352, 1641-1647.	4.3	52
27	Recent updates in the discovery and development of novel antimalarial drug candidates. <i>MedChemComm</i> , 2018, 9, 437-453.	3.4	52
28	Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 9890-9905.	6.4	51
29	MalDA, Accelerating Malaria Drug Discovery. <i>Trends in Parasitology</i> , 2021, 37, 493-507.	3.3	51
30	2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and <i>Mycobacterium tuberculosis</i> : Structure-Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization. <i>ACS Infectious Diseases</i> , 2018, 4, 954-969.	3.8	49
31	Plasmodial Kinase Inhibitors: License to Cure?. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8061-8077.	6.4	49
32	Synthesis and Antiplasmodial and Antimycobacterial Evaluation of New Nitroimidazole and Nitroimidazooxazine Derivatives. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 128-131.	2.8	47
33	Primaquine-pyrimidine hybrids: Synthesis and dual-stage antiplasmodial activity. <i>European Journal of Medicinal Chemistry</i> , 2015, 101, 266-273.	5.5	47
34	Pyrimidine-chloroquinoline hybrids: Synthesis and antiplasmodial activity. <i>European Journal of Medicinal Chemistry</i> , 2018, 148, 39-53.	5.5	44
35	Medicinal Chemistry Optimization of Antiplasmodial Imidazopyridazine Hits from High Throughput Screening of a SoftFocus Kinase Library: Part 1. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 2789-2798.	6.4	43
36	Synthesis and structure-activity-relationship studies of thiazolidinediones as antiplasmodial inhibitors of the <i>Plasmodium falciparum</i> cysteine protease falcipain-2. <i>European Journal of Medicinal Chemistry</i> , 2015, 90, 507-518.	5.5	43

#	ARTICLE	IF	CITATIONS
37	The quest for the holy grail: new antitubercular chemical entities, targets and strategies. <i>Drug Discovery Today</i> , 2020, 25, 772-780.	6.4	43
38	Reversed Chloroquines Based on the 3,4-Dihydropyrimidin-2(1 <i>H</i> )-one Scaffold: Synthesis and Evaluation for Antimalarial, $\text{P}^{2\text{-H}}$ Haematin Inhibition, and Cytotoxic Activity. <i>ChemMedChem</i> , 2008, 3, 1649-1653.	3.2	41
39	Structure-Activity-Relationship Studies around the 2-Amino Group and Pyridine Core of Antimalarial 3,5-Diarylamino-pyridines Lead to a Novel Series of Pyrazine Analogues with Oral in Vivo Activity. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 8860-8871.	6.4	41
40	Aminopyrazolo[1,5- <i>a</i> ]pyrimidines as potential inhibitors of <i>Mycobacterium tuberculosis</i> : Structure activity relationships and ADME characterization. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 7240-7250.	3.0	41
41	UCT943, a Next-Generation <i>Plasmodium falciparum</i> PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	40
42	Identification, Characterization, and Optimization of 2,8-Disubstituted-1,5-naphthyridines as Novel <i>Plasmodium falciparum</i> Phosphatidylinositol-4-kinase Inhibitors with in Vivo Efficacy in a Humanized Mouse Model of Malaria. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5692-5703.	6.4	40
43	Ferrocene-pyrimidine conjugates: Synthesis, electrochemistry, physicochemical properties and antiplasmodial activities. <i>European Journal of Medicinal Chemistry</i> , 2015, 100, 1-9.	5.5	39
44	Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel <i>Plasmodium</i> Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	39
45	<i>Plasmodium</i> Kinases as Potential Drug Targets for Malaria: Challenges and Opportunities. <i>ACS Infectious Diseases</i> , 2021, 7, 518-534.	3.8	39
46	Synthesis, antimycobacterial evaluation and pharmacophore modeling of analogues of the natural product formononetin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2510-2513.	2.2	37
47	Structure-Activity Relationship Studies of Orally Active Antimalarial 3,5-Substituted 2-Aminopyridines. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 11022-11030.	6.4	36
48	Fragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitors. <i>Clinical Science</i> , 2014, 126, 305-313.	4.3	36
49	Antimalarial Pyrido[1,2- <i>a</i> ]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1432-1448.	6.4	36
50	Synthesis of novel keto-ACE analogues as domain-selective angiotensin I-converting enzyme inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 4612-4615.	2.2	35
51	Synthesis and Evaluation of a Carbosilane Congener of Ferroquine and Its Corresponding Half-Sandwich Ruthenium and Rhodium Complexes for Antiplasmodial and $\text{P}^{2\text{-H}}$ -Haematin Inhibition Activity. <i>Organometallics</i> , 2014, 33, 4345-4348.	2.3	35
52	Structure-activity relationship studies of antiplasmodial cyclometallated ruthenium(II), rhodium(III) and iridium(III) complexes of 2-phenylbenzimidazoles. <i>European Journal of Medicinal Chemistry</i> , 2019, 161, 11-21.	5.5	35
53	Synthesis and molecular modeling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting enzyme. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 4616-4619.	2.2	34
54	Benzoheterocyclic amodiaquine analogues with potent antiplasmodial activity: Synthesis and pharmacological evaluation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5046-5050.	2.2	33

#	ARTICLE	IF	CITATIONS
55	Medicinal Chemistry Optimization of Antiplasmodial Imidazopyridazine Hits from High Throughput Screening of a SoftFocus Kinase Library: Part 2. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 8839-8848.	6.4	33
56	Design, Synthesis, and Antiplasmodial Activity of Hybrid Compounds Based on (2 <i>R</i> ,3 <i>S</i> )- <i>N</i> -Benzoyl-3-phenylisoserine. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 637-641.	2.8	32
57	A Novel Pyrazolopyridine with in Vivo Activity in <i>Plasmodium berghei</i> - and <i>Plasmodium falciparum</i> -Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 8713-8722.	6.4	32
58	The Tuberculosis Drug Accelerator at year 10: what have we learned?. <i>Nature Medicine</i> , 2021, 27, 1333-1337.	30.7	32
59	Synthesis of new verapamil analogues and their evaluation in combination with rifampicin against <i>Mycobacterium tuberculosis</i> and molecular docking studies in the binding site of efflux protein Rv1258c. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 2985-2990.	2.2	31
60	Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids. <i>European Journal of Medicinal Chemistry</i> , 2015, 101, 52-62.	5.5	29
61	Synthesis and antiplasmodial evaluation of aziridine-(iso)quinoline hybrids and their ring-opening products. <i>MedChemComm</i> , 2013, 4, 724.	3.4	27
62	Effects of a domain-selective ACE inhibitor in a mouse model of chronic angiotensin II-dependent hypertension. <i>Clinical Science</i> , 2014, 127, 57-63.	4.3	27
63	Synthesis of functionalized 3-, 5-, 6- and 8-aminoquinolines via intermediate (3-pyrrolin-1-yl)- and (2-oxopyrrolidin-1-yl)quinolines and evaluation of their antiplasmodial and antifungal activity. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 91-102.	5.5	27
64	Plasmeprin Inhibitors in Antimalarial Drug Discovery: Medicinal Chemistry and Target Validation (2000) <i>Trends in Pharmacology and Therapeutics</i> , 2000, 21, 10-17.	6.45	27
65	Synthesis and biological evaluation of 4 arylcoumarin analogues as tubulin-targeting antitumor agents. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 1652-1665.	3.0	26
66	Synthesis and biological evaluation of novel quinoline-piperidine scaffolds as antiplasmodium agents. <i>European Journal of Medicinal Chemistry</i> , 2020, 198, 112330.	5.5	26
67	Synthesis, Antiplasmodial Activity, and $\text{I}^2$ -Hematin Inhibition of Hydroxypyridone-Chloroquine Hybrids. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 642-646.	2.8	25
68	Insights into Integrated Lead Generation and Target Identification in Malaria and Tuberculosis Drug Discovery. <i>Accounts of Chemical Research</i> , 2017, 50, 1606-1616.	15.6	25
69	Design and synthesis of novel ferrocene-quinoline conjugates and evaluation of their electrochemical and antiplasmodium properties. <i>European Journal of Medicinal Chemistry</i> , 2020, 187, 111963.	5.5	24
70	The Synthesis of Parasitic Cysteine Protease and Trypanothione Reductase Inhibitors. <i>Current Medicinal Chemistry</i> , 2003, 10, 1863-1889.	2.4	23
71	Crystal structures of sampatrilat and sampatrilat-Asp in complex with human ACE: a molecular basis for domain selectivity. <i>FEBS Journal</i> , 2018, 285, 1477-1490.	4.7	23
72	New Verapamil Analogs Inhibit Intracellular Mycobacteria without Affecting the Functions of Mycobacterium-Specific T Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1216-1225.	3.2	22

#	ARTICLE	IF	CITATIONS
73	Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure–Activity Relationship and Target Identification Studies. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 10118-10134.	6.4	22
74	Semisynthetic Antimycobacterial C-3 Silicate and C-3/C-21 Ester Derivatives of Fusidic Acid: Pharmacological Evaluation and Stability Studies in Liver Microsomes, Rat Plasma, and <i>Mycobacterium tuberculosis</i> culture. <i>ACS Infectious Diseases</i> , 2019, 5, 1634-1644.	3.8	22
75	Antimalarial Pyrido[1,2-a]benzimidazole Derivatives with Mannich Base Side Chains: Synthesis, Pharmacological Evaluation, and Reactive Metabolite Trapping Studies. <i>ACS Infectious Diseases</i> , 2019, 5, 372-384.	3.8	22
76	Antimalarial aminothiazoles and aminopyridines from phenotypic whole-cell screening of a SoftFocus library. <i>Future Medicinal Chemistry</i> , 2012, 4, 2265-2277.	2.3	21
77	Antimicrobial evaluation of neutral and cationic iridium(III) and rhodium(III) aminoquinoline-benzimidazole hybrid complexes. <i>European Journal of Medicinal Chemistry</i> , 2020, 206, 112694.	5.5	21
78	4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant <i>Plasmodium falciparum</i> and Exhibit Oral Activity in Mice. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 10245-10256.	6.4	20
79	The Design and Development of a Potent and Selective Novel Diprolyl Derivative That Binds to the N-Domain of Angiotensin-I Converting Enzyme. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 344-359.	6.4	20
80	Novel antimycobacterial C-21 amide derivatives of the antibiotic fusidic acid: synthesis, pharmacological evaluation and rationalization of media-dependent activity using molecular docking studies in the binding site of human serum albumin. <i>MedChemComm</i> , 2019, 10, 961-969.	3.4	20
81	Economic drug discovery and rational medicinal chemistry for tropical diseases. <i>Pure and Applied Chemistry</i> , 2005, 77, 1957-1964.	1.9	19
82	Synthesis of halogenated 4-quinolones and evaluation of their antiplasmodial activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1214-1217.	2.2	19
83	Antimalarial benzoheterocyclic 4-aminoquinolines: Structure–activity relationship, in vivo evaluation, mechanistic and bioactivation studies. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 5419-5432.	3.0	19
84	Synthesis and biological characterisation of ester and amide derivatives of fusidic acid as antiplasmodial agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 658-661.	2.2	19
85	Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized <i>Plasmodium falciparum</i> NODscidIL2R <sup>−/−</sup> Mouse Model of Malaria. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4213-4227.	6.4	19
86	Potent <i>Plasmodium falciparum</i> gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1279-1290.	3.0	19
87	Azaaurones as Potent Antimycobacterial Agents Active against MDR- and XDR-TB. <i>ChemMedChem</i> , 2019, 14, 1537-1546.	3.2	19
88	Synthesis and in Vitro and in Vivo Pharmacological Evaluation of New 4-Aminoquinoline-Based Compounds. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 1198-1202.	2.8	18
89	Synthesis of fusidic acid bioisosteres as antiplasmodial agents and molecular docking studies in the binding site of elongation factor-G. <i>MedChemComm</i> , 2015, 6, 2023-2028.	3.4	18
90	Design, Synthesis, and Evaluation of Novel Hybrid Efflux Pump Inhibitors for Use against <i>Mycobacterium tuberculosis</i> . <i>ACS Infectious Diseases</i> , 2016, 2, 714-725.	3.8	18

#	ARTICLE	IF	CITATIONS
91	Benzimidazole Derivatives Are Potent against Multiple Life Cycle Stages of <i>Plasmodium falciparum</i> Malaria Parasites. <i>ACS Infectious Diseases</i> , 2021, 7, 1945-1955.	3.8	18
92	Exploration of thiaheterocyclic HDAC6 inhibitors as potential antiplasmodial agents. <i>Future Medicinal Chemistry</i> , 2017, 9, 357-364.	2.3	17
93	The Next Generation Scientist program: capacity-building for future scientific leaders in low- and middle-income countries. <i>BMC Medical Education</i> , 2018, 18, 233.	2.4	17
94	Synthesis and synergistic antimycobacterial screening of chlorpromazine and its metabolites. <i>MedChemComm</i> , 2014, 5, 502-506.	3.4	16
95	Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 4453-4461.	3.0	16
96	Esterase phenotyping in human liver <i>in vitro</i> : specificity of carboxylesterase inhibitors. <i>Xenobiotica</i> , 2016, 46, 862-867.	1.1	16
97	Interaction of the red pigment-concentrating hormone of the crustacean <i>Daphnia pulex</i> , with its cognate receptor, Dappu-RPCHR: A nuclear magnetic resonance and modeling study. <i>International Journal of Biological Macromolecules</i> , 2018, 106, 969-978.	7.5	16
98	Multistage Antiplasmodium Activity of Astemizole Analogues and Inhibition of Hemozoin Formation as a Contributor to Their Mode of Action. <i>ACS Infectious Diseases</i> , 2019, 5, 303-315.	3.8	16
99	Synthesis, Structure-Activity Relationship, and Mechanistic Studies of Aminoquinazolinones Displaying Antimycobacterial Activity. <i>ACS Infectious Diseases</i> , 2020, 6, 1951-1964.	3.8	16
100	Antimalarial Benzimidazole Derivatives Incorporating Phenolic Mannich Base Side Chains Inhibit Microtubule and Hemozoin Formation: Structure-Activity Relationship and <i>In Vivo</i> Oral Efficacy Studies. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5198-5215.	6.4	16
101	Developing Synergistic Drug Combinations To Restore Antibiotic Sensitivity in Drug-Resistant <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	16
102	Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6903-6925.	6.4	16
103	Cell-Based Medicinal Chemistry Optimization of High Throughput Screening Hits for Orally Active Antimalarials. Part 2: Hits from SoftFocus Kinase and other Libraries. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7750-7754.	6.4	15
104	Antischistosomal Activity of Pyrido[1,2- <i>a</i> ]benzimidazole Derivatives and Correlation with Inhibition of $\text{F}_2$ -Hematin Formation. <i>ACS Infectious Diseases</i> , 2017, 3, 411-420.	3.8	15
105	Synthesis and evaluation of the performance of a small molecule library based on diverse tropane-related scaffolds. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115442.	3.0	15
106	High-Throughput Crystallography Reveals Boron-Containing Inhibitors of a Penicillin-Binding Protein with Di- and Tricovalent Binding Modes. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 11379-11394.	6.4	15
107	Structure-Activity Relationship Studies of Orally Active Antimalarial 2,4-Diamino-thienopyrimidines. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7572-7579.	6.4	14
108	Structural Basis for Inhibitor Potency and Selectivity of <i>Plasmodium falciparum</i> Phosphatidylinositol 4-Kinase Inhibitors. <i>ACS Infectious Diseases</i> , 2020, 6, 3048-3063.	3.8	14

#	ARTICLE	IF	CITATIONS
109	The Plasmodium falciparum ABC transporter ABCI3 confers parasite strain-dependent pleiotropic antimalarial drug resistance. Cell Chemical Biology, 2022, 29, 824-839.e6.	5.2	14
110	The adipokinetic hormones and their cognate receptor from the desert locust, <i>Schistocerca gregaria</i>: solution structure of endogenous peptides and models of their binding to the receptor. PeerJ, 2019, 7, e7514.	2.0	14
111	Kojic acid derived hydroxypyridinone-chloroquine hybrids: Synthesis, crystal structure, antiplasmodial activity and P2-haematin inhibition. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3263-3267.	2.2	13
112	Cocrystal and Salt Forms of an Imidazopyridazine Antimalarial Drug Lead. Journal of Pharmaceutical Sciences, 2019, 108, 2349-2357.	3.3	13
113	New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of <i>Plasmodium</i> Phosphatidylinositol-4-kinase and cGMP-Dependent Protein Kinase. ACS Infectious Diseases, 2021, 7, 34-46.	3.8	13
114	1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in <i>Mycobacterium tuberculosis</i>. Journal of Medicinal Chemistry, 2021, 64, 12790-12807.	6.4	13
115	Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones. Antimicrobial Agents and Chemotherapy, 2022, 66, e0219221.	3.2	13
116	Effect of Varying the Anionic Component of a Copper(I) Catalyst on Homologation of Arylacetylenes to Allenes by the Mannich Reaction. European Journal of Organic Chemistry, 2008, 2008, 43-46.	2.4	12
117	Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor. European Journal of Pharmaceutical Sciences, 2014, 56, 113-119.	4.0	12
118	The Dynamic Nonprime Binding of Sampatrilat to the C-Domain of Angiotensin-Converting Enzyme. Journal of Chemical Information and Modeling, 2016, 56, 2486-2494.	5.4	12
119	Design, synthesis, and <i>In vitro</i> antituberculosis activity of 2(5<i>H</i>)-Furanone derivatives. IUBMB Life, 2016, 68, 612-620.	3.4	12
120	Intestinal Transport Characteristics and Metabolism of C-Glucosyl Dihydrochalcone, Aspalathin. Molecules, 2017, 22, 554.	3.8	12
121	Structure-Activity Relationship and <i>In Vitro</i> Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) Studies of <i>N</i>-aryl 3-Trifluoromethyl Pyrido[1,2- <i>a&lt;/i&gt;]benzimidazoles That Are Efficacious in a Mouse Model of Schistosomiasis. ACS Infectious Diseases, 2019, 5, 418-429.</i>	3.8	12
122	Pharmacokinetics and Organ Distribution of C-3 Alkyl Esters as Potential Antimycobacterial Prodrugs of Fusidic Acid. ACS Infectious Diseases, 2020, 6, 459-466.	3.8	12
123	New ketomethylene inhibitor analogues: synthesis and assessment of structural determinants for N-domain selective inhibition of angiotensin-converting enzyme. Biological Chemistry, 2012, 393, 485-493.	2.5	11
124	Antiplasmodial activity, in vivo pharmacokinetics and anti-malarial efficacy evaluation of hydroxypyridinone hybrids in a mouse model. Malaria Journal, 2015, 14, 505.	2.3	11
125	3D-QSAR Modeling and Synthesis of New Fusidic Acid Derivatives as Antiplasmodial Agents. Journal of Chemical Information and Modeling, 2018, 58, 1553-1560.	5.4	11
126	Incorporation of an intramolecular hydrogen bonding motif in the side chain of antimalarial benzimidazoles. MedChemComm, 2019, 10, 450-455.	3.4	11



#	ARTICLE	IF	CITATIONS
127	Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and <i>In Vivo</i> Efficacy in the <i>Plasmodium falciparum</i> NSG Mouse Model. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13013-13030.	6.4	11
128	Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?. <i>RSC Medicinal Chemistry</i> , 2020, 11, 455-490.	3.9	11
129	Structure-activity relationship analyses of fusidic acid derivatives highlight crucial role of the C-21 carboxylic acid moiety to its anti-mycobacterial activity. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115530.	3.0	11
130	Expanding the Activity Profile of Pyrido[1,2- <i>a</i> ]benzimidazoles: Synthesis and Evaluation of Novel <i>N</i> <sup>1</sup> -1-Phenylethanamine Derivatives against <i>Schistosoma mansoni</i> . <i>ACS Infectious Diseases</i> , 2021, 7, 1032-1043.	3.8	11
131	Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite <i>Plasmodium falciparum</i> and Optimization Efforts. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 2291-2309.	6.4	11
132	Identification of steroid-like natural products as antiplasmodial agents by 2D and 3D similarity-based virtual screening. <i>MedChemComm</i> , 2017, 8, 1152-1157.	3.4	10
133	Synthesis and biological evaluation of aryl-oxadiazoles as inhibitors of <i>Mycobacterium tuberculosis</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1758-1764.	2.2	10
134	Antiplasmodial imidazopyridazines: structure-activity relationship studies lead to the identification of analogues with improved solubility and hERG profiles. <i>MedChemComm</i> , 2018, 9, 1733-1745.	3.4	10
135	Intrinsic fluorescence properties of antimalarial pyrido[1,2- <i>a</i> ]benzimidazoles facilitate subcellular accumulation and mechanistic studies in the human malaria parasite <i>Plasmodium falciparum</i> . <i>Organic and Biomolecular Chemistry</i> , 2020, 18, 8668-8676.	2.8	10
136	Lerisetron Analogues with Antimalarial Properties: Synthesis, Structure-Activity Relationship Studies, and Biological Assessment. <i>ACS Omega</i> , 2020, 5, 6967-6982.	3.5	10
137	Benzoheterocyclic Oxime Carbamates Active against <i>Mycobacterium tuberculosis</i> : Synthesis, Structure-Activity Relationship, Metabolism, and Biology Triaging. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 9444-9457.	6.4	10
138	Evaluation of Ferrocenyl-Containing Benzothiazoles as Potential Antiplasmodial Agents. <i>European Journal of Inorganic Chemistry</i> , 2017, 2017, 242-246.	2.0	9
139	Antimalarial Lead-Optimization Studies on a 2,6-Imidazopyridine Series within a Constrained Chemical Space To Circumvent Atypical Dose-Response Curves against Multidrug Resistant Parasite Strains. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 9371-9385.	6.4	9
140	Antitubercular 2-Pyrazolylpyrimidinones: Structure-Activity Relationship and Mode-of-Action Studies. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 719-740.	6.4	9
141	Rv0684/ <i>fusA1</i> , an Essential Gene, Is the Target of Fusidic Acid and Its Derivatives in <i>Mycobacterium tuberculosis</i> . <i>ACS Infectious Diseases</i> , 2021, 7, 2437-2444.	3.8	9
142	Fostering drug discovery and development in Africa. <i>Nature Medicine</i> , 2022, 28, 1523-1526.	30.7	9
143	Antiplasmodial drug targets: a patent review (2000 - 2013). <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 107-130.	5.0	8
144	Reversed isoniazids: Design, synthesis and evaluation against <i>Mycobacterium tuberculosis</i> . <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 833-844.	3.0	8

#	ARTICLE	IF	CITATIONS
145	Five Solid Forms of a Potent Imidazopyridazine Antimalarial Drug Lead: A Preformulation Study. <i>Crystal Growth and Design</i> , 2019, 19, 4683-4697.	3.0	8
146	Structure-Activity Relationship Studies and <i>Plasmodium</i> Life Cycle Profiling Identifies Pan-Active <i>N</i> -Aryl-3-trifluoromethyl Pyrido[1,2- <i>a</i> ]benzimidazoles Which Are Efficacious in an <i>In Vivo</i> Mouse Model of Malaria. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1022-1035.	6.4	8
147	Alternative solid-state forms of a potent antimalarial aminopyridine: X-ray crystallographic, thermal and solubility aspects. <i>CrystEngComm</i> , 2014, 16, 5781-5792.	2.6	7
148	Bioisosteric ferrocenyl-containing quinolines with antiplasmodial and antitrichomonal properties. <i>Dalton Transactions</i> , 2016, 45, 19086-19095.	3.3	7
149	A preformulation co-crystal screening case study: Polymorphic co-crystals of an imidazopyridazine antimalarial drug lead with the cofomer succinic acid. <i>Journal of Molecular Structure</i> , 2020, 1204, 127561.	3.6	7
150	Medicinal Chemistry Out of Africa. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10513-10516.	6.4	7
151	Structure-Activity Relationship Studies Reveal New Astemizole Analogues Active against <i>Plasmodium falciparum</i> <i>In Vitro</i> . <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1333-1341.	2.8	7
152	Exploring the Antiplasmodial $\alpha$ -Aminopyridines as Potential Antitrypanosomal Agents. <i>ChemMedChem</i> , 2019, 14, 2034-2041.	3.2	6
153	Structure elaboration of isoniazid: synthesis, <i>in silico</i> molecular docking and antimycobacterial activity of isoniazid-pyrimidine conjugates. <i>Molecular Diversity</i> , 2020, 24, 949-955.	3.9	6
154	Molecular Structure of an Unexpected Binuclear Salicylaldehyde Semicarbazone Palladium(II) Complex. <i>Journal of Chemical Crystallography</i> , 2011, 41, 747-750.	1.1	5
155	Synthesis of metergoline analogues and their evaluation as antiplasmodial agents. <i>MedChemComm</i> , 2014, 5, 165-170.	3.4	5
156	Investigating Sulfoxide-to-Sulfone Conversion as a Prodrug Strategy for a Phosphatidylinositol 4-Kinase Inhibitor in a Humanized Mouse Model of Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	5
157	New developments in anti-infectives research for tropical infectious diseases. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 5085-5086.	3.0	4
158	Carbon-14 radiolabeling and tissue distribution evaluation of MMV390048. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2016, 59, 680-688.	1.0	4
159	Antimalarial Activities of (Z)-2-(Nitroheteroarylmethylene)-3(2H)-Benzofuranone Derivatives: <i>In Vitro</i> and <i>In Vivo</i> Assessment and $\beta$ -Hematin Formation Inhibition Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0268320.	3.2	4
160	Quinine fever. <i>Nature Chemistry</i> , 2022, , .	13.6	4
161	Pharmacologically Relevant Bifunctional Compounds Containing Chloroquinoline and Dihydropyrimidone Moieties: Syntheses and Crystal Structures of a Target Molecule and Selected Intermediates. <i>Journal of Chemical Crystallography</i> , 2009, 39, 753-760.	1.1	3
162	Preparation and Physicochemical Characterization of an Inclusion Complex Between Dimethylated $\beta$ -Cyclodextrin and a Drug Lead From a New Class of Orally Active Antimalarial 3,5-Diaryl-2-Aminopyridines. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 3344-3350.	3.3	3

#	ARTICLE	IF	CITATIONS
163	Characterisation of artemisinin-chloroquinoline hybrids for potential metabolic liabilities. <i>Xenobiotica</i> , 2016, 46, 234-240.	1.1	3
164	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes. <i>Molecules</i> , 2017, 22, 743.	3.8	3
165	Probing the Requirements for Dual Angiotensin-Converting Enzyme C-Domain Selective/Nepriylsin Inhibition. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3371-3387.	6.4	3
166	A Chemical Approach Towards Understanding the Mechanism and Reversal of Drug Resistance in <i>Plasmodium falciparum</i> : Is it Viable?. <i>IUBMB Life</i> , 2002, 53, 249-252.	3.4	2
167	Structure-activity relationship studies of antiplasmodial aminomethylthiazoles. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5207-5211.	2.2	2
168	Data for the homology modelling of the red pigment-concentrating hormone receptor (Dappu-RPCHR) of the crustacean <i>Daphnia pulex</i> , and docking of its cognate agonist (Dappu-RPCH). <i>Data in Brief</i> , 2017, 15, 941-947.	1.0	2
169	Implications of <i>Mycobacterium tuberculosis</i> Metabolic Adaptability on Drug Discovery and Development. <i>ACS Infectious Diseases</i> , 2022, 8, 414-421.	3.8	2
170	Innovation Experiences from Africa-Led Drug Discovery at the Holistic Drug Discovery and Development (H3D) Centre. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 1221-1230.	2.8	2
171	A Pharmacokinetic Study of Antimalarial 3,5-Diaryl-2-aminopyridine Derivatives. <i>Malaria Research and Treatment</i> , 2015, 2015, 1-5.	2.0	1
172	Medicinal chemistry progression of antimalarial hits from phenotypic whole cell screening of SoftFocus libraries. <i>Annual Reports in Medicinal Chemistry</i> , 2019, , 25-71.	0.9	1
173	Stuart Warren (24 Dec 1938-22 Mar 2020). <i>Organic and Biomolecular Chemistry</i> , 2020, 18, 7236-7237.	2.8	1
174	Synthesis and In Vitro Antiprotozoan Evaluation of 4-/8-Aminoquinoline-based Lactams and Tetrazoles. <i>Molecules</i> , 2020, 25, 5941.	3.8	1
175	Chemogenomic Fingerprints Associated with Stage-Specific Gametocytocidal Compound Action against Human Malaria Parasites. <i>ACS Infectious Diseases</i> , 2021, 7, 2904-2916.	3.8	1
176	Exploring the transmission-blocking activity of antiplasmodial 3,6-diarylated imidazopyridazines. <i>Transactions of the Royal Society of South Africa</i> , 0, , 1-9.	1.1	1
177	Structural Rigidification of <i>N</i> -Aryl-pyrroles into Indoles Active against Intracellular and Drug-Resistant Mycobacteria. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 63-69.	2.8	1
178	Antimalarial Pyrido[1,2- <i>a</i> ]benzimidazoles Exert Strong Parasiticidal Effects by Achieving High Cellular Uptake and Suppressing Heme Detoxification. <i>ACS Infectious Diseases</i> , 2022, 8, 1700-1710.	3.8	1
179	Keystone Malaria Symposium 2022: a vibrant discussion of progress made and challenges ahead from drug discovery to treatment. <i>Trends in Parasitology</i> , 2022, 38, 711-718.	3.3	1
180	Crystallisation of an Unexpected Trinuclear Heteronuclear Carbosilane Congener of Ferroquine. <i>Journal of Chemical Crystallography</i> , 2015, 45, 202-206.	1.1	0

#	ARTICLE	IF	CITATIONS
181	Cell-Based Medicinal Chemistry Optimization of High Throughput Screening Hits towards Orally Active Antimalarial and Antituberculosis Agents. Proceedings (mdpi), 2017, 1, .	0.2	0
182	Introduction to the 1st Molecules Medicinal Chemistry Symposium (MMCS), Barcelona, 8 September 2017. Proceedings (mdpi), 2017, 1, .	0.2	0
183	Special Issue on Epigenetic Modulation Approaches in Infectious Diseases. ACS Infectious Diseases, 2020, 6, 2813-2814.	3.8	0
184	Simplifying Submission Requirements for the Journal of Medicinal Chemistry. Journal of Medicinal Chemistry, 2021, 64, 7877-7878.	6.4	0